Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

This study is testing whether giving immunotherapy drugs nivolumab and relatlimab before surgery (neoadjuvant) can shrink cutaneous squamous cell carcinoma (a type of skin cancer) and improve surgical outcomes. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of cutaneous squamous cell carcinoma (skin cancer, not head and neck mucosal) - Your cancer is at stage II, III, or IV and is considered surgically removable - Your tumor is measurable on scans **You may NOT be eligible if...** - Your cancer has spread to distant organs beyond the regional lymph nodes - You have active autoimmune diseases that would be worsened by immunotherapy - You have had prior treatment with drugs targeting the same immune pathways (PD-1/LAG-3) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.